Berkeley researcher Jay Keasling and his team have developed a synthetic form of the most commonly used malaria drug — artemisinin, which until now had to be extracted from the wormwood plant.
In partnership with One World Health and the Bill and Melinda Gates Foundation, scientists use synthetic biology to produce artemisinin from the bacteria E. coli in huge brewery like tanks.
“The goal is to increase the supply, then stabilize the price, then lower the price substantially,” Keasling said.
Researchers from the Sanger Institute pinpointed a single receptor for a protein that is critical for the parasite to gain entry into red blood cells before multiplying and spreading.
Blocking it could halt the killer disease in its tracks and may prove a good way to design a vaccine, they said, although this could take another decade or so to become a reality.
Global Markets Direct’s, ‘Malaria – Pipeline Review, H2 2011’, provides an overview of the Malaria therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. ‘Malaria – Pipeline Review, H2 2011’ is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
– A snapshot of the global therapeutic scenario for Malaria.
– A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
– Coverage of products based on various stages of development ranging from discovery till registration stages.
– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
– Coverage of the Malaria pipeline on the basis of route of administration and molecule type.
– Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
– Key discontinued pipeline projects.
– Latest news and deals relating to the products.
Reasons to buy
– Identify and understand important and diverse types of therapeutics under development for Malaria.
With mostly adults dying of dengue, there is evidence to suggest that paediatricians are a lot better in following the guidelines set by the Epidemiology Unit and preventing deaths, said another doctor, asking whether it is lethargy or complacency or negligence on the part of physicians.
It can’t be ignorance because over and over again they have been told what should be done and that is very simple, another pointed out. The first step is to monitor all febrile patients (those coming in with fever) as the first suspect on the diagnosis list should be dengue, the Sunday Times understands, as dengue has become hyper-endemic.
The policy should be to think of all patients with fever as having dengue, unless ruled otherwise, it is learnt. Clinicians should monitor the febrile phase very carefully and then check out whether it is dengue fever (DF) or dengue haemorrhagic fever (DHF) when the fever has continued for more than three days, said a senior doctor who has studied dengue. DF has no plasma leakage, while in DHF there will be evidence of both a plasma leakage and a platelet count equal to or below 100,000/c.mm. Many patients with DF and DHF will also have a white blood cell count below 5,000.
The other important factor is that dengue patients do not need to be accommodated in an intensive care unit but can be managed in a ward. However, constant monitoring is the key, another doctor pointed out.
Researchers on Sunday reported initial signs of success from the first release into the environment of mosquitoes engineered to pass a lethal gene to their offspring, killing them before they reach adulthood.
The results, and other work elsewhere, could herald an age in which genetically modified insects will be used to help control agricultural pests and insect-borne diseases like dengue fever and malaria.
But the research is arousing concern about possible unintended effects on public health and the environment, because once genetically modified insects are released, they cannot be recalled.
One of the most comprehensive analyses yet done of the ancient history of insect-borne disease concludes for the first time that malaria is not only native to the New World, but it has been present long before humans existed and has evolved through birds and monkeys.
The findings, presented in a recent issue of American Entomologist by researchers from Oregon State University, are based on the study of insect specimens preserved in amber.
The study outlines the evolution of several human diseases, including malaria, leishmaniasis and trypanosomiasis. It makes clear that these pathogens have existed for at least 100 million years, and suggests that efforts to conquer them will be an uphill battle against such formidable and adaptive foes.